Compare Novo Nordisk A/S (NVO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Williams-Sonoma, Inc. — how do they compare? Novo Nordisk A/S trades at $46.4 (market cap $207.85B), while Williams-Sonoma, Inc. trades at $250.52 (market cap $29.51B). The key difference: Novo Nordisk A/S is far larger — about 7× Williams-Sonoma, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | WSM | |
|---|---|---|
Market Cap | $207.85B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $251.81 |
52-Week Low | $35.29 | $168.64 |
Enterprise Value | $222.55B | $30.35B |
Dividend Yield | 3.81% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Williams-Sonoma (WSM) trades at $245.16, down 2.26% today, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 13.81% net income margin and 54.01% ROE, supported by recent earnings beats. Recent news highlights investor interest and a CEO stock sale, while cash flow trends show variability, with 2025 net cash flow at -$49 million.
Outlook remains positive with consistent earnings performance and a 'Moderate Buy' analyst consensus, though risks include consumer discretionary sector volatility and competitive pressures. The stock trades above the consensus price target of $231.10, suggesting limited near-term upside based on current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
